共 343 条
[1]
Arnould L(2006)Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94 259-267
[2]
Gelly M(1990)Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 4087-4091
[3]
Penault-Llorca F(1991)Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease Am J Obstet Gynecol 164 15-21
[4]
Benoit L(1983)Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 10-17
[5]
Bonnetain F(2009)Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc Natl Acad Sci USA 106 22299-22304
[6]
Migeon C(2014)HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges Arch Pathol Lab Med 138 343-350
[7]
Cabaret V(2013)Integrated genomic characterization of endometrial carcinoma Nature 497 67-73
[8]
Fermeaux V(1998)NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res 58 5123-5129
[9]
Bertheau P(1999)Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells Cancer Res 59 1196-1201
[10]
Garnier J(2006)Therapeutic targets: MTOR and related pathways Cancer Biol Ther 5 1065-1073